The AI Gold Rush in Healthcare: A Reality Check
The healthcare industry is currently experiencing an AI gold rush, with investors, providers, and payers directing substantial funds toward new technologies. However, a gathering of top healthcare CFOs and industry leaders at the Healthcare Financial Management Association’s (HFMA) annual conference suggests that many of these investments may fall short of expectations.
The Infrastructure Challenge
The issue does not necessarily lie with the AI tools themselves but rather with the integration of these sophisticated models into outdated infrastructure. Seema Verma, former CMS administrator and general manager of Oracle Health & Life Sciences, succinctly states, “Without a data strategy, there is no AI strategy.”
Verma highlights that the infrastructure most healthcare providers work with today is too outdated to support AI’s needs, which include access to unified, real-time data across clinical, financial, and operational systems. For instance, a doctor relying on AI recommendations needs real-time data on a patient’s health insurance coverage, medication availability, and potential drug interactions.
Without this essential connectivity, even the most robust AI tools will underperform, Verma warns.
The Weight of Legacy Systems
Mike Marks, CFO of HCA Healthcare, one of the largest health systems in the country, echoes Verma’s concerns, emphasizing that the vast technical debt is hindering progress. He states, “The amount of legacy systems we all deal with really hinders transformation.”
Replacing technology on this scale is prohibitively expensive. The demand for AI innovations already surpasses a health system’s financial capacity, underscoring the importance of establishing a solid foundation. Marks prioritizes clinical systems first, followed by operations and administrative functions.
This patient-centered logic focuses on clinical systems because they directly impact healthcare delivery, leading to immediate health outcomes improvements. Operational and administrative functions, while important, should support a system already delivering high-quality care.
Marks highlights that underperforming clinical AI has direct consequences for patients, necessitating significant investment and oversight.
The “Bot versus Bot” Dilemma
Scott Hawig, another healthcare CFO from BJC Healthcare, agrees that the industry has a long way to go before AI fulfills its potential. He describes the current scenario as a battle between payers and providers, with “two sets of bots, each deployed by opposing sides, fighting endlessly for claims, with no one winning.”
Hawig refers to the “bot versus bot” problem: the provider’s revenue cycle bot versus the denial insurance bot, which he identifies as a fundamental issue.
The AI tools are present, investment capital is flowing, and the urgency is palpable. However, experts caution that investing heavily without first addressing the data infrastructure could be an expensive way to remain stagnant.
For further details, visit Here.
“`
